87 related articles for article (PubMed ID: 17596729)
1. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients.
Churchill DN; Macarios D; Attard C; Kallich J; Goeree R
Nephron Clin Pract; 2007; 106(4):c193-8. PubMed ID: 17596729
[TBL] [Abstract][Full Text] [Related]
2. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.
Choy CK; Spencer AP; Nappi JM
Pharmacotherapy; 2007 May; 27(5):707-14. PubMed ID: 17461706
[TBL] [Abstract][Full Text] [Related]
4. A strategy to reduce inflammation and anemia treatment's related costs in dialysis patients.
Di Iorio BR; Di Micco L; Russo L; Nardone L; De Simone E; Sirico ML; Di Natale G; Russo D
G Ital Nefrol; 2018 Feb; 35(1):. PubMed ID: 29390245
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
6. The marginal cost of satellite versus in-center hemodialysis.
Soroka SD; Kiberd BA; Jacobs P
Hemodial Int; 2005 Apr; 9(2):196-201. PubMed ID: 16191069
[TBL] [Abstract][Full Text] [Related]
7. A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy.
McFarlane PA; Hillmer MP; Dacouris N
Nephron Clin Pract; 2007; 107(3):c90-6. PubMed ID: 17890876
[TBL] [Abstract][Full Text] [Related]
8. Is it time to reconsider subcutaneous administration of epoetin?
Patel TV; Robinson K; Singh AK
Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
[TBL] [Abstract][Full Text] [Related]
9. [Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review].
Ranchon F; Hédoux S; Laville M; Fouque D; Decullier E; Chapuis F; Huot L
Nephrol Ther; 2010 Apr; 6(2):97-104. PubMed ID: 20097148
[TBL] [Abstract][Full Text] [Related]
10. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study.
Burnier M; Douchamps JA; Tanghe A; Demey J; Perrault L; Foster CE; Robbins S
J Med Econ; 2009 Jun; 12(2):77-86. PubMed ID: 19450138
[TBL] [Abstract][Full Text] [Related]
11. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
Holloway M
Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
[TBL] [Abstract][Full Text] [Related]
12. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of treatment with epoietin-alpha for patients with anaemia due to renal failure: the case of Sweden.
Glenngård AH; Persson U; Schön S
Scand J Urol Nephrol; 2008; 42(1):66-73. PubMed ID: 17907051
[TBL] [Abstract][Full Text] [Related]
15. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
16. Hemodialysis cost in Tehran, Iran.
Mahdavi-Mazdeh M; Zamani M; Zamyadi M; Rajolani H; Tajbakhsh K; Heidary Rouchi A; Aghighi M; Mahdavi A
Hemodial Int; 2008 Oct; 12(4):492-8. PubMed ID: 19090872
[TBL] [Abstract][Full Text] [Related]
17. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
[TBL] [Abstract][Full Text] [Related]
19. Reducing hemodialysis costs: conventional and quotidian home hemodialysis in Canada.
McFarlane PA
Semin Dial; 2004; 17(2):118-24. PubMed ID: 15043613
[TBL] [Abstract][Full Text] [Related]
20. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
